In Q1 FY2026 (ended March 31, 2026), Absci Corp reported revenue of $215,000, a decline of 81.8% year-over-year. Net loss widened to $29.6 million, and operating loss was $30.8 million. Diluted EPS was -$0.19, improving 9.5% from the prior year. Cash stood at $8.6 million, with equity of $172.0 million and no long-term debt.
•Revenue fell 81.8% YoY to $215,000.
•Net loss increased 12.3% to $29.6 million.
•Diluted EPS improved 9.5% to -$0.19.
•Cash and equivalents were $8.6 million; no long-term debt.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Absci Corporation, a clinical-stage biopharmaceutical company develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease.
Its portfolio also includes ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia, ABS-301 for the treatment of immuno-oncology, and ABS-501 for treating oncology.
Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint R&D activities. Founded in 2011, the company is headquartered in Vancouver, Washington.
Absci Corporation is a clinical-stage biopharmaceutical company based in the United States that develops antibody therapeutics. Its main focus is on creating treatments for various diseases, including inflammatory conditions, hair loss, and cancers. The company's preclinical development programs include ABS-101, an antibody for inflammatory bowel disease currently in Phase 1 clinical trials, and ABS-201, an anti-prolactin receptor antibody for androgenic alopecia in Phase 1/2a trials. Additionally, Absci is developing ABS-301 for immuno-oncology and ABS-501 for oncology. The company collaborates with several organizations such as PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities.
Where is Absci Corporation listed and what currency does it trade in?
Absci Corporation is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol ABSI. The company's shares are traded in United States Dollars (USD). As a US-based company listed on a major US exchange, its stock is accessible to investors through standard brokerage accounts that offer access to Nasdaq-listed securities.
What sector and industry does Absci Corporation operate in?
Absci Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. Biotechnology companies like Absci use biological processes and living organisms to develop medical treatments, including antibody-based therapies. As a clinical-stage biopharmaceutical company, Absci focuses on research and development of novel therapeutics, with its pipeline targeting areas such as inflammatory bowel disease, alopecia, and oncology. The biotechnology industry is known for its high research intensity and potential for breakthrough treatments.
Where is Absci Corporation headquartered and what is its geographic focus?
Absci Corporation is headquartered in Vancouver, Washington, United States. The company primarily operates within the United States, as indicated by its country and region designation. While its collaborations extend to partners like PrecisionLife and Memorial Sloan Kettering Cancer Center, the company's main operations and clinical trials are based in the US. The geographic focus is on developing antibody therapeutics for global markets, but the headquarters and core activities are centered in the US.
What are some notable collaborations and pipeline programs of Absci Corporation?
Absci Corporation has several notable collaborations and a diversified pipeline of antibody therapeutics. The company's preclinical programs include ABS-101 for inflammatory bowel disease (Phase 1), ABS-201 for androgenic alopecia (Phase 1/2a), ABS-301 for immuno-oncology, and ABS-501 for oncology. Absci engages in joint R&D activities with partners such as PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. These collaborations leverage expertise in areas like data analytics, genomics, and computing to advance drug discovery. The company's business model focuses on developing these therapeutics through clinical trials, with the goal of eventually bringing them to market.